# Modeling pediatric brain tumors with human stem cells

**Authors:** Noah Burket, Titto Augustine, Jignesh Tailor

PMC · DOI: 10.3389/fncel.2026.1720855 · Frontiers in Cellular Neuroscience · 2026-02-11

## TL;DR

This paper reviews how human stem cells are used to model common pediatric brain tumors and study their biology.

## Contribution

The paper highlights the use of human stem cells to understand gene mutations and tumor initiation in pediatric brain cancers.

## Key findings

- Human stem cells are used to model glioma, medulloblastoma, and ependymoma in organoid and xenotransplantation systems.
- These models help identify functional consequences of gene mutations and potential drug targets in pediatric brain tumors.
- Stem cell models complement mouse studies to explore early stages of tumor development in a human context.

## Abstract

With recent advances in stem cell technology, there has been an expansion of human stem and progenitor cell models of pediatric brain tumors, including use of human pluripotent and embryonic stem cells both in organoid cultures and following xenotransplantation in mice. In this review, we discuss the current approaches to modelling pediatric brain cancers using stem cells. While brain tumors describe a broad set of disease entities, we focus on glioma, medulloblastoma and ependymoma, as these are not only the most common malignant brain tumor types but also have the most stem cell models currently available. We examine human stem cell-based modeling approaches and discuss the biological questions that are being addressed using these state-of-the-art tools. Specifically, we focus on the unique advantage of using these cells to understand the functional consequences of gene mutations and their downstream growth-promoting pathways within the cell in a human context. These approaches are needed to ascertain the key players that are functionally relevant in the initiation and propagation of these tumors at the gene and protein level and to identify new drug targets. Moreover, human stem cell-based modeling approaches may complement studies in genetically engineered mouse models to address fundamental questions in tumor biology, particularly the early stages of tumorigenesis.

## Linked entities

- **Diseases:** glioma (MONDO:0021042), medulloblastoma (MONDO:0002794), ependymoma (MONDO:0003478)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, IDH1 (isocitrate dehydrogenase (NADP(+)) 1) [NCBI Gene 3417] {aka HEL-216, HEL-S-26, IDCD, IDH, IDP, IDPC}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, PDGFRA (platelet derived growth factor receptor alpha) [NCBI Gene 5156] {aka CD140A, PDGFR-2, PDGFR2}, CTCF (CCCTC-binding factor) [NCBI Gene 10664] {aka CFAP108, FAP108, MRD21}, CDK4 (cyclin dependent kinase 4) [NCBI Gene 1019] {aka CMM3, MCPH31, PSK-J3}, SHH (sonic hedgehog signaling molecule) [NCBI Gene 6469] {aka HHG1, HLP3, HPE3, MCOPCB5, SMMCI, ShhNC}, NF1 (neurofibromin 1) [NCBI Gene 4763] {aka NFNS, VRNF, WSS}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, CXCL10 (C-X-C motif chemokine ligand 10) [NCBI Gene 3627] {aka C7, IFI10, INP10, IP-10, SCYB10, crg-2}, OTX2 (orthodenticle homeobox 2) [NCBI Gene 5015] {aka CPHD6, MCOPS5}, ATOH1 (atonal bHLH transcription factor 1) [NCBI Gene 474] {aka ATH1, DFNA89, HATH1, MATH-1, bHLHa14}, GFI1 (growth factor independent 1 transcriptional repressor) [NCBI Gene 2672] {aka GFI-1, GFI1A, SCN2, ZNF163}, KIAA1549 (KIAA1549) [NCBI Gene 57670] {aka RP86}, KIT (KIT proto-oncogene, receptor tyrosine kinase) [NCBI Gene 3815] {aka C-Kit, CD117, MASTC, PBT, SCFR}, NANOG (Nanog homeobox) [NCBI Gene 79923], MAP2K7 (mitogen-activated protein kinase kinase 7) [NCBI Gene 5609] {aka JNKK2, MAPKK7, MEK, MEK 7, MKK7, PRKMK7}, POU5F1 (POU class 5 homeobox 1) [NCBI Gene 5460] {aka OCT3, OCT4, OCT4Borf1, OTF-3, OTF3, OTF4}, KDM3B (lysine demethylase 3B) [NCBI Gene 51780] {aka 5qNCA, C5orf7, DIJOS, JMJD1B, NET22}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, DDX3X (DEAD-box helicase 3 X-linked) [NCBI Gene 1654] {aka CAP-Rf, DBX, DDX14, DDX3, HLP2, MRX102}, BRAF (B-Raf proto-oncogene, serine/threonine kinase) [NCBI Gene 673] {aka B-RAF1, B-raf, BRAF-1, BRAF1, NS7, RAFB1}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, RB1 (RB transcriptional corepressor 1) [NCBI Gene 5925] {aka OSRC, PPP1R130, RB, p105-Rb, p110-RB1, pRb}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, ATRX (ATRX chromatin remodeler) [NCBI Gene 546] {aka JMS, MRX52, RAD54, RAD54L, XH2, XNP}, SOX2 (SRY-box transcription factor 2) [NCBI Gene 6657] {aka ANOP3, MCOPS3}, PROM1 (prominin 1) [NCBI Gene 8842] {aka AC133, CD133, CORD12, MCDR2, MSTP061, PROML1}, PTCH1 (patched 1) [NCBI Gene 5727] {aka BCNS, BCNS1, NBCCS, PTC, PTC1, PTCH}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, RAG1 (recombination activating 1) [NCBI Gene 5896] {aka RAG-1, RNF74}, DICER1 (dicer 1, ribonuclease III) [NCBI Gene 23405] {aka DCR1, Dicer, Dicer1e, GLOW, HERNA, K12H4.8-LIKE}, SMARCB1 (SWI/SNF related BAF chromatin remodeling complex subunit B1) [NCBI Gene 6598] {aka BAF47, CSS3, INI-1, INI1, MRD15, PPP1R144}, GSE1 (Gse1 coiled-coil protein) [NCBI Gene 23199] {aka CRHSP24, KIAA0182}, MYCN (MYCN proto-oncogene, bHLH transcription factor) [NCBI Gene 4613] {aka FGLDS1, MODED, MPAPA, MYCNsORF, MYCNsPEP, N-myc}, KLF4 (KLF transcription factor 4) [NCBI Gene 9314] {aka EZF, GKLF}
- **Diseases:** neurofibromatosis (type 1 &amp; 2) (MESH:D016518), Pineoblastoma (MESH:D010871), Li-Fraumeni (MESH:D016864), ATRTs (MESH:C000597569), LGGs (MESH:D008228), breast cancer (MESH:D001943), papilloma (MESH:D010212), NES (MESH:D018302), astrocytic gliomas (MESH:D001254), severe combined immunodeficiency (MESH:D016511), papillary tumors (MESH:D002291), brain cancers (MESH:D001932), carcinogenic (MESH:D011230), tumorigenic (MESH:D002471), CPT (MESH:C535588), pituitary lesions (MESH:D010900), CNS tumors (MESH:D016543), choroid plexus carcinoma (MESH:D020288), derived tumors (MESH:C536408), tumorigenesis (MESH:D063646), nervous system tumors (MESH:D009423), MB (OMIM:613675), hypoxic (MESH:D002534), Hypoxia (MESH:D000860), Group 3 medulloblastomas (MESH:D008527), Ependymoma (MESH:D004806), CNS GCTs (MESH:D009373), inherited tumor (MESH:D009386), Craniopharyngiomas (MESH:D003397), CPTs (MESH:D016545), DMG (MESH:D005910), anaplastic tumors (MESH:D002277), Gorlin (MESH:D001478), pituitary adenomas (MESH:D010911), Tumors (MESH:D009369), diabetic (MESH:D003920)
- **Chemicals:** N-nitrosourea (-), methylcholanthrene (MESH:D008748), oxygen (MESH:D010100)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** R132H, K27M, R175H, V600E, G34R
- **Cell lines:** Gorlin — Homo sapiens (Human), Nevoid basal cell carcinoma syndrome, Transformed cell line (CVCL_WA79), SHH MB — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_IQ83)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12932252/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12932252/full.md

## References

166 references — full list in the complete paper: https://tomesphere.com/paper/PMC12932252/full.md

---
Source: https://tomesphere.com/paper/PMC12932252